What is Repare Therapeutics?
Repare Therapeutics is a leading clinical-stage precision oncology company that leverages its proprietary synthetic lethality approach to discover and develop novel therapeutics. At the core of its technological advantage is the SNIPRx platform, a genome-wide, CRISPR-enabled system designed to systematically identify and target vulnerabilities in cancer cells. By focusing on genomic instability and DNA damage repair, the company is uniquely positioned to develop highly targeted therapies that offer improved efficacy and safety profiles compared to traditional oncology treatments. This scientific rigor has established Repare as a key player in the next generation of cancer research, bridging the gap between fundamental genomic discovery and clinical application.
How much funding has Repare Therapeutics raised?
Repare Therapeutics has raised a total of $150.5M across 2 funding rounds:
Series A
$68M
Series B
$82.5M
Series A (2017): $68M with participation from Celgene Switzerland, Versant Ventures, Fonds de solidaritu00e9 FTQ, and MPM Capital
Series B (2019): $82.5M led by Versant Ventures, Logos Capital, Cowen Healthcare Investments, OrbiMed, BVF Partners L.P, Fonds de solidarité FTQ, MPM Capital, BDC Capital, and Redmile
Key Investors in Repare Therapeutics
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies around the world, leveraging over $5.5 billion under management and a deep track record of successful IPOs and M&A transactions.
MPM Capital
MPM BioImpact manages early-stage venture funds and public impact funds, focusing on converting complex scientific research into viable therapeutics for patients with significant unmet medical needs.
OrbiMed
OrbiMed is a specialized healthcare investment firm with deep expertise across biopharmaceuticals and medical devices, providing both capital and operational insights to support companies through various stages of development.
What's next for Repare Therapeutics?
With the support of its recent strategic investment, Repare Therapeutics is well-positioned to accelerate its clinical development programs and expand its therapeutic portfolio. The company is expected to prioritize the advancement of its lead candidates through human trials while continuing to refine its SNIPRx platform to identify new targets within the DNA damage repair pathway. As the firm moves deeper into the clinical-stage lifecycle, the focus will likely shift toward strategic partnerships and potential commercialization pathways, leveraging its robust intellectual property and data-driven discovery engine to maintain its competitive edge in the rapidly evolving precision medicine market.
See full Repare Therapeutics company page
